Other OTC - Delayed Quote USD

NervGen Pharma Corp. (NGENF)

1.5500 +0.0200 (+1.31%)
At close: May 13 at 3:30 PM EDT
Currency in CAD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
17,776.7100
17,776.7100
23,025.0330
12,811.2240
11,195.8840
Operating Income
-17,776.7100
-17,776.7100
-23,025.0330
-12,811.2240
-11,195.8840
Net Non Operating Interest Income Expense
550.0740
550.0740
-313.2030
29.4170
18.8520
Other Income Expense
-5,155.4840
-5,155.4840
2,615.9530
55.2290
-9.1090
Pretax Income
-22,382.1200
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Net Income Common Stockholders
-22,382.1200
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Diluted NI Available to Com Stockholders
-22,382.1200
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Basic EPS
-0.38
--
-0.39
-0.32
-0.35
Diluted EPS
-0.38
--
-0.39
-0.32
-0.35
Basic Average Shares
59,290.0470
--
52,649.0350
39,289.2240
32,111.6980
Diluted Average Shares
59,290.0470
--
52,649.0350
39,289.2240
32,111.6980
Total Expenses
17,776.7100
17,776.7100
23,025.0330
12,811.2240
11,195.8840
Net Income from Continuing & Discontinued Operation
-22,382.1200
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Normalized Income
-17,226.6360
-17,226.6360
-23,338.2360
-12,781.8070
-11,177.0320
Interest Income
550.0740
550.0740
201.3960
29.4170
18.8520
Interest Expense
--
--
514.5990
--
--
Net Interest Income
550.0740
550.0740
-313.2030
29.4170
18.8520
EBIT
-22,382.1200
-22,382.1200
-20,207.6840
-12,726.5780
-11,195.8840
EBITDA
-22,237.1180
-22,237.1180
-20,092.5700
-12,683.9520
-11,156.2390
Reconciled Depreciation
145.0020
145.0020
115.1140
42.6260
39.6450
Net Income from Continuing Operation Net Minority Interest
-22,382.1200
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Total Unusual Items Excluding Goodwill
-5,155.4840
-5,155.4840
2,615.9530
55.2290
-9.1090
Total Unusual Items
-5,155.4840
-5,155.4840
2,615.9530
55.2290
-9.1090
Normalized EBITDA
-17,081.6340
-17,081.6340
-22,708.5230
-12,739.1810
-11,147.1300
12/31/2020 - 4/3/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ACXP Acurx Pharmaceuticals, Inc.
2.0900
+2.96%
 
MDNAF Medicenna Therapeutics Corp.
1.8300
+1.10%
 
NYMXF Nymox Pharmaceutical Corporation
0.3109
+20.97%
 
CAPR Capricor Therapeutics, Inc.
5.44
+2.64%
 
CWBR CohBar, Inc.
0.9999
+31.55%
 
ELEV Elevation Oncology, Inc.
3.5400
+7.93%
 
RZLT Rezolute, Inc.
2.8500
-4.68%
 
ONCO Onconetix, Inc.
0.1134
+6.98%
 
BRCTF BioArctic AB (publ)
18.89
+4.50%
 
KNBIF Kane Biotech Inc.
0.0939
0.00%